Comcast (NASDAQ:CMCSA) shares firm Tuesday as the company is contemplating a deal with Japanese electronics maker Sharp. Sharp would build liquid crystal display (LCD) televisions with a built-in cable channel receiver, Kyodo reported. The Japanese news agency said Sharp is trying to pursuing growth by focusing on its sluggish LCD TV operations. Comcast did not…
Myriad Genetics (NASDAQ:MYGN) is lower after the molecular diagnostic company disclosed in a regulatory filing Tuesday that the U.S. District Court for the District of Utah has denied the company’s motion for preliminary injunctive relief against Ambry Genetics’s sale of certain testing services that MYGN believes infringes on its patents. Shares are down 9.80% at…
Health Net (NYSE:HNT), a managed care company, disclosed in a regulatory filing Monday that it will be reaffirming its earnings guidance for fiscal 2014 at the Barclays Global Healthcare Conference on Tuesday. The company had previously said that it is expecting fiscal 2014 earnings of at least $3.00 per share and revenue of $14.4 billion….
Shares of National Bank of Greece (NYSE:NBG) are up nearly 10% Monday following Deutsche Bank’s new coverage of the stock at a Buy rating and EUR4.50 price target (approx $6.25 based on Monday’s exchange rate). The rating results from Deutsche Bank’s forecast for a strong recovery in fundamentals for the Greek banking sector. In addition,…
In a note issued Friday, Piper Jaffray said the weakness in Regeneron (NASDAQ:REGN) is a buying opportunity, as the firm sees risks to the company’s alirocumab Phase III program as overblown, with neither Regeneron (NASDAQ:REGN) or its development partner Sanofi (SNY) having seen any neurocognitive adverse events with the drug. The firm reiterates a Buy rating…
Shares in Northwest Biotherapeutics (NASDAQ:NWBO), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, have jumped 12% pre-market after the company said the Data Safety Monitoring Board has recommended its Phase III trial into a lethal form of brain cancer continue. The company’s lead program is a 312-patient Phase III trial in…
